Showing results (11-20 of 610) with videos related to
Sort By:
Pageof 61
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerRodrigo Dienstmann, Ramon Salazar, Josep TaberneroOncotarget|February 15, 2011
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogsBen Markman, Rodrigo Dienstmann, Josep TaberneroAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in OncologyElena Garralda, Rodrigo Dienstmann, Josep TaberneroMolecular Oncology|August 2, 2014
Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the testRodrigo Dienstmann, Jordi Rodon, Josep TaberneroFuture Oncology (London, England)|April 21, 2012
Panitumumab: a summary of clinical development in colorectal cancer and future directionsGuillem Argiles, Rodrigo Dienstmann, Elena Elez, et al.Clinical Colorectal Cancer|July 7, 2011
Development of molecular biomarkers in individualized treatment of colorectal cancerLeticia De Mattos-Arruda, Rodrigo Dienstmann, Josep TaberneroRecent Patents on Anti-Cancer Drug Discovery|February 8, 2011
Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2Rodrigo Dienstmann, Jordi Rodon, Ben Markman, et al.Nature Reviews. Clinical Oncology|February 13, 2013
Development of PI3K inhibitors: lessons learned from early clinical trialsJordi Rodon, Rodrigo Dienstmann, Violeta Serra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Genomic medicine frontier in human solid tumors: prospects and challengesRodrigo Dienstmann, Jordi Rodon, Jordi Barretina, et al.The Oncologist|December 3, 2011
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugsRodrigo Dienstmann, Irene Braña, Jordi Rodon, et al.Pageof 61